Kiren Kresa-Reahl

Cladribine tablets added to IFN-β in active relapsing MS

Xavier Montalbán, Thomas Leist, Bruce A. Cohen et al. · Neurology Neuroimmunology & Neuroinflammation · 2018 · 63 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Andrew Goodman, François Béthoux, Theodore R. Brown et al. · Multiple Sclerosis Journal · 2015 · 51 citations · Full text

Health Professions, Pharmacotherapy, Clinical Pharmacology +16

The relationship between objective parameters of sleep and measures of fatigue, depression, and cognition in multiple sclerosis

RA Sater, Mark Gudesblatt, Kiren Kresa-Reahl et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2015 · 45 citations · Full text

Medicine, Neurology, Neuroscience +16

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study

Kiren Kresa-Reahl, Pavle Repovic, Derrick Robertson et al. · Clinical Therapeutics · 2018 · 35 citations

Medicine, Neurology, Pharmacology +11

Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center

Kyle Smoot, Kateri J. Spinelli, Tamela Stuchiner et al. · Multiple Sclerosis Journal · 2017 · 25 citations

Medicine, Neurology, Pharmacotherapy +16